AstraZeneca PLC (LON:AZN - Get Free Report) insider Pascal Soriot purchased 20,000 shares of the firm's stock in a transaction on Thursday, November 14th. The shares were acquired at an average cost of £102.03 ($128.58) per share, with a total value of £2,040,600 ($2,571,644.61).
AstraZeneca Stock Performance
LON AZN traded down GBX 314 ($3.96) during trading hours on Friday, reaching GBX 9,978 ($125.75). The company's stock had a trading volume of 3,164,543 shares, compared to its average volume of 3,928,471. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. The business has a 50-day simple moving average of £117.03 and a 200 day simple moving average of £121.32. AstraZeneca PLC has a 52 week low of GBX 9,461 ($119.23) and a 52 week high of £133.88 ($168.72). The stock has a market cap of £154.66 billion, a PE ratio of 3,172.49, a PEG ratio of 0.86 and a beta of 0.17.
Wall Street Analyst Weigh In
A number of analysts have recently commented on AZN shares. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a £110 ($138.63) target price on shares of AstraZeneca in a research report on Tuesday, September 3rd. Shore Capital restated a "buy" rating on shares of AstraZeneca in a research report on Thursday, November 7th. JPMorgan Chase & Co. restated an "overweight" rating and issued a £140 ($176.43) price target on shares of AstraZeneca in a research report on Thursday, November 7th. Finally, Berenberg Bank reiterated a "buy" rating and set a £150 ($189.04) target price on shares of AstraZeneca in a research report on Monday, September 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of £104.12 ($131.22).
Check Out Our Latest Analysis on AstraZeneca
AstraZeneca Company Profile
(
Get Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
